- Home
- UPWK vs AVTX Comparison
UPWK vs AVTX Comparison
Compare UPWK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPWK | AVTX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 956.7M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UPWK | AVTX |
|---|---|---|
| Price | $9.43 | $18.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $22.73 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 3.1M | 869.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $787,784,000.00 | $27,813,137.00 |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $13.57 | N/A |
| P/E Ratio | $39.96 | ★ N/A |
| Revenue Growth | 2.40 | ★ 2312.27 |
| 52 Week Low | $7.44 | $8.29 |
| 52 Week High | $22.84 | $24.27 |
Technical Indicators
Market Signals| Indicator | UPWK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.